Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.
Seppic MONTANIDE ISA 720 is a metabolizable oil adjuvant that has given good results in animals with recombinant malarial antigens. Twelve human volunteers were given increasing intramuscular doses of MONTANIDE ISA 720, ranging from 0.6 to 1.8 ml. The adjuvant was well tolerated with only minor local effects, including tenderness, local swelling and discomfort on use. MONTANIDE ISA 720 may prove to be an acceptable and effective adjuvant for use in people.
Lawrence
G W
GW
Tropical Health Program, Queensland Institute of Medical Research, Brisbane, Australia.
Saul
A
A
Giddy
A J
AJ
Kemp
R
R
Pye
D
D
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D000328:Adult; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D017780:Malaria Vaccines / Q000276:immunology; D008297:Male; D008353:Mannitol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000276:immunology; D008875:Middle Aged; D009821:Oils; D009829:Oleic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*
D000276:Adjuvants, Immunologic; D017780:Malaria Vaccines; D009821:Oils; D009829:Oleic Acids; C001681:mannide monooleate; D008353:Mannitol